Literature DB >> 12966353

Prostate cancer in African American men is associated with downregulation of zinc transporters.

Irum Rishi1, Hasna Baidouri, Jamil A Abbasi, Rebecca Bullard-Dillard, Andre' Kajdacsy-Balla, Joseph P Pestaner, Marek Skacel, Raymond Tubbs, Omar Bagasra.   

Abstract

In the United States, prostate cancer is the most commonly diagnosed male cancer and the second leading cause of all male cancer deaths. Furthermore, incidence rates are higher in African Americans than in any other racial group. Our laboratory is attempting to decipher the environmental and molecular mechanisms involved in the development of prostate cancer in African Americans. Because Africa is a mineral-rich continent, and the zinc levels in the water and diet are high, it is hypothesized that Africans may have genetically downregulated their zinc absorption capacity; otherwise, they would absorb abnormally high levels of zinc, resulting in various serious neurodegenerative and biochemical disorders. It is therefore possible that people of African origin may have a lower capacity to absorb zinc when compared with other racial groups because of their inherent downregulation of zinc transporters. Extensive research has shown that low serum levels of zinc are associated with the increased incidence of prostate cancer. We have evaluated 58 prostate cancer tissues in 2 major racial groups (30 from whites and 28 from African Americans) for their ability to express 2 major human zinc transporters, hZIP1 and hZIP2. In all 30 prostate cancer specimens obtained from white people, the degree of expression of these 2 zinc receptors was high when compared with age-matched and Gleason score-matched specimens obtained from African American patients. We also found a significant downregulation of these 2 zinc transporters in normal prostate tissues from African American men when compared with age-matched white men. The loss of the unique ability to retain normal intracellular levels of zinc may be an important factor in the development and progression of prostate cancer. Our observation that the uptake of zinc may be different in racial groups is intriguing and relevant. Once these data are confirmed in larger groups, this finding could have significant application as a preventive maneuver for at least for some people. Because dietary zinc supplements are relatively nontoxic, any efficacy trial would be low-risk.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12966353     DOI: 10.1097/00129039-200309000-00009

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  39 in total

Review 1.  Role of zinc in the pathogenesis and treatment of prostate cancer: critical issues to resolve.

Authors:  L C Costello; P Feng; B Milon; M Tan; R B Franklin
Journal:  Prostate Cancer Prostatic Dis       Date:  2004       Impact factor: 5.554

Review 2.  Altered metabolism and mitochondrial genome in prostate cancer.

Authors:  G D Dakubo; R L Parr; L C Costello; R B Franklin; R E Thayer
Journal:  J Clin Pathol       Date:  2006-01       Impact factor: 3.411

Review 3.  Zinc and zinc transporters in normal prostate and the pathogenesis of prostate cancer.

Authors:  Renty B Franklin; Beatrice Milon; Pei Feng; Leslie C Costello
Journal:  Front Biosci       Date:  2005-09-01

4.  Zinc transporter genes and urological cancers: integrated analysis suggests a role for ZIP11 in bladder cancer.

Authors:  Lang Wu; Kari G Chaffee; Alexander S Parker; Hugues Sicotte; Gloria M Petersen
Journal:  Tumour Biol       Date:  2015-04-23

5.  Reassessment of the Transport Mechanism of the Human Zinc Transporter SLC39A2.

Authors:  Marie C Franz; Jonai Pujol-Giménez; Nicolas Montalbetti; Miguel Fernandez-Tenorio; Timothy R DeGrado; Ernst Niggli; Michael F Romero; Matthias A Hediger
Journal:  Biochemistry       Date:  2018-06-07       Impact factor: 3.162

6.  DNA methylation profiles in African American prostate cancer patients in relation to disease progression.

Authors:  Rohina Rubicz; Shanshan Zhao; Milan Geybels; Jonathan L Wright; Suzanne Kolb; Brandy Klotzle; Marina Bibikova; Dean Troyer; Raymond Lance; Elaine A Ostrander; Ziding Feng; Jian-Bing Fan; Janet L Stanford
Journal:  Genomics       Date:  2016-02-21       Impact factor: 5.736

7.  Reversal of epigenetic silencing of AP-2alpha results in increased zinc uptake in DU-145 and LNCaP prostate cancer cells.

Authors:  Peter B Makhov; Konstantin V Golovine; Alexander Kutikov; Daniel J Canter; Vera A Rybko; Dmitry A Roshchin; Vsevolod B Matveev; Robert G Uzzo; Vladimir M Kolenko
Journal:  Carcinogenesis       Date:  2011-09-22       Impact factor: 4.944

8.  Case-only gene-environment interaction between ALAD tagSNPs and occupational lead exposure in prostate cancer.

Authors:  Christine Neslund-Dudas; Albert M Levin; Andrew Rundle; Jennifer Beebe-Dimmer; Cathryn H Bock; Nora L Nock; Michelle Jankowski; Indrani Datta; Richard Krajenta; Q Ping Dou; Bharati Mitra; Deliang Tang; Benjamin A Rybicki
Journal:  Prostate       Date:  2014-02-05       Impact factor: 4.104

9.  Marginal zinc deficiency increases oxidative DNA damage in the prostate after chronic exercise.

Authors:  Yang Song; Valerie Elias; Andrei Loban; Angus G Scrimgeour; Emily Ho
Journal:  Free Radic Biol Med       Date:  2009-10-28       Impact factor: 7.376

Review 10.  Zinc and zinc transporters in prostate carcinogenesis.

Authors:  Vladimir Kolenko; Ervin Teper; Alexander Kutikov; Robert Uzzo
Journal:  Nat Rev Urol       Date:  2013-03-12       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.